Investigation of the role of estrogen receptor and progesterone receptor gene expressions in the occurrence of endometrial proliferative processes to address the issue of management tactics for patients with these pathological changes in the endometrium

Savel'eva G.M.

Kafedra akusherstva i ginekologii pediatricheskogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, kafedra akusherstva i ginekologii fakul'teta fundamental'noĭ meditsiny Moskovskogo gosudarstvennogo universiteta im. M.V. Lomonosova

Breusenko V.G.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

Kareva E.N.

Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation;
First Moscow State Medical University of the Ministry of Health of the Russian Federation

SPIN RSCI: 2105-2701
Scopus AuthorID: 6701781417
ResearcherID: E-9011-2014
ORCID: 0000-0002-9441-3468

Ivanovskaya T.N.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

Kochina N.A.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

Gutorova D.S.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

Investigation of the role of estrogen receptor and progesterone receptor gene expressions in the occurrence of endometrial proliferative processes to address the issue of management tactics for patients with these pathological changes in the endometrium

Authors:

Savel'eva G.M., Breusenko V.G., Kareva E.N., Ivanovskaya T.N., Kochina N.A., Gutorova D.S.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2018;18(6): 17‑24

DOI: 10.17116/rosakush20181806117

Downloaded: 53

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Savel'eva GM, Breusenko VG, Kareva EN, Ivanovskaya TN, Kochina NA, Gutorova DS. Investigation of the role of estrogen receptor and progesterone receptor gene expressions in the occurrence of endometrial proliferative processes to address the issue of management tactics for patients with these pathological changes in the endometrium. Russian Bulletin of Obstetrician-Gynecologist. 2018;18(6):17‑24. (In Russ.)
https://doi.org/10.17116/rosakush20181806117

Подписка 2025 (Russian Bulletin of Obstetrician-Gynecologist)

Close metadata

Objective — to assess the role of gene expression of the estrogen receptors (ER) (mER, ERα, and ERβ) and progesterone receptors (PR) (mPR, PGRmC1, PR-A, and PR-B) in the occurrence of endometrial proliferative processes (EPPs) (simple and atypical endometrial hyperplasia and adenocarcinoma) in postmenopausal patients to address the issues of their management tactics. Subject and methods. Examinations were made in 53 patients with EPPs: hyperplasia without atypia (n=7), hyperplasia with atypia (n=6), moderate-grade adenocarcinoma (n=31), and low-grade adenocarcinoma (n=9). A control group consisted of 29 patients with endometrial fibroglandular polyps (EFGPs). The endometrial tissue expressions of the mER, ERα, ERb, mPR, PGRmC1, PR-A, and PR-B genes were determined by a real-time polymerase chain reaction assay in the study and control groups. Results. The endometrial expressions of the ERβ, mPR, PR-A, PR-B receptor genes were higher in endometrial hyperplasia with and without atypia than those in EFGPs in the control group. The expression of ERα in the tissue of adenocarcinoma and endometrial hyperplasia with atypia was significantly lower than that in the control group. The expressions of ERα, ERβ, PGRmC1, PR-A, PR-B in the tissue of endometrial hyperplasia without atypia were higher than that in moderate-grade and low-grade adenocarcinoma. The expression of mPR in the tissue of endometrial hyperplasia without atypia was significantly higher than that in moderate-grade adenocarcinoma, as well as the expression of PGRmC1 and PR-A was higher than that in adenocarcinoma. Conclusion. The findings open up new opportunities in investigating the potential personalized use of not only progestagens, but can also, possibly, aromatase inhibitors that are more commonly administered in ER-positive endometrial adenocarcinoma. Treatment choices depend on the individual ER/PR expression ratio in the removed hyperplastic endometrium without atypia. Free full text in English on web-site: https://www.mediasphera.ru/journal/rossijskij-vestnik-akushera-ginekologa

Keywords:

endometrial proliferative processes; endometrial hyperplasia without atypia; endometrial hyperplasia with atypia; moderate-grade adenocarcinoma; low-grade adenocarcinoma; postmenopause; mER

ERα

ERß

mPR

PGRmC1

PR-A

PR-B

Authors:

Savel'eva G.M.

Breusenko V.G.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

Kareva E.N.

Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation;
First Moscow State Medical University of the Ministry of Health of the Russian Federation

SPIN RSCI: 2105-2701
Scopus AuthorID: 6701781417
ResearcherID: E-9011-2014
ORCID: 0000-0002-9441-3468

Ivanovskaya T.N.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

Kochina N.A.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

Gutorova D.S.

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russia

List of references:

Clinical oncogynecology. 2 edition, supplemented and revised. Ed. Kozachenko VP. Moscow: Binom Russia. 2016:424. (In Russ.)
Malignant neoplasms in Russia in 2015 (morbidity and mortality). Ed. Kaprin AD, Starinskii VV, Petrova GV. Moscow: P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia. 2017;250 (In Russ.)
Postmenopause. Physiology and pathology. Savel´eva GM, Breusenko VG, Kappusheva LM. Vestnik Rossiiskoi assotsiatsii akusherov-ginecologov. 1998;2:45-49. (In Russ.)
Strizhakov AN, Kushlinskii NE, Shakhlamova MN, Isaeva EA, Kolosov EA, Roshchina EG. Differentiated approach to the diagnosis and tactics of management of endometrial hyperplastic processes in postmenopausal women. Voprosy gynekologii, akusherstva i perinatologii. 2014;13:1:5-13. (In Russ.)
Breusenko VG, Kareva EN, Golukhov GN, Ivanovskaya TN, Golova YuA, Kotsyubinskaya NA, Bekhbudova LKh, Stepanov KI, Vorob´eva GYu. Endometrial proliferative processes in pre- and postmenopausal patients. Impact of abnormal proliferation on the endometrial steroid receptor profile. Rossiiskii vestnik akushera-ginekologa. 2016;16:4:25-31. (In Russ.) https://doi.org/10.17116/rosakush201616425-31
Kreizman-Shefer H, Pricop J, Goldman S, Elmalah I, Shalev E. Distribution of estrogen and progesterone receptors isoforms in endometrial cancer. Diagn Pathol. 2014;9:77. PMCID: PMC4022268 https://doi.org/10.1186/1746-1596-9-77
Mylonas I, Jeschke U, Shabani N, Kuhn C, Kriegel S, Kupka MS, Friese K. Normal and malignant human endometrium express Immunohistochemically estrogen receptor alpha (ER–), estrogen receptor beta (ER–‚) and progesterone receptor (PR). Anticancer Research. 2005;25:1679-1686. First Department of Obstetrics and Gynecology, Ludwig, Maximilians, University Munich, Germany.
Kavandi L, Ivanova VS, Nguyen H and Syed V. Abstract 4549: Expression and localization of progesterone receptor membrane component 1 and 2 in normal and malignant endometrial cells. Cancer Research. 2011;71: 8:45-49. https://doi.org/10.1158/1538-7445.am2011-4549
Skrzypczak M, Schüler S, Lattrich C, Ignatov A, Ortmann O, Treeck O. G protein-coupled estrogen receptor (GPER) expression in endometrial adenocarcinoma and effect of agonist G-1 on growth of endometrial adenocarcinoma cell lines. Steroids. 2013; 78:11:1087-1091. https://doi.org/10.1016/j.steroids.2013.07.007
Petrie WK, Dennis MK, Hu C, Dai D, Arterburn JB, Smith HO, Hathaway HJ, Prossnitz E. G Protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth. Obstet Gynecol Int. 2013;1-17. PMCID: PMC3863501 https://doi.org/10.1155/2013/472720
Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, Birkeland E, Raeder MB, Oyan AM, Stefansson IM, Kalland KH, Akslen LA, Salvesen HB. Loss of GPER identifies new targets for therapy among a subgroup of ER_α-positive endometrial cancer patients with poor outcome. Br J Cancer. 2012;106:1682-1688. https://doi.org/10.1038/bjc.2012.91
Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004;95:1:133-138. https://doi.org/10.1016/j.ygyno.2004.06.045
Shabani N, Kuhn C. Prognostic significance of oestrogen receptor alpha (ER_α) and beta (ER_β), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer. 2007;43:16: 2434-2444. https://doi.org/10.1016/j.ejca.2007.08.014
Gwen E. Dressing, Yefei Pang, Jing Dong. Progestin signaling through mPRα in atlantic croaker granulosa/theca cell cocultures and Its involvement in progestin inhibition of apoptosis. Endocrinology. 2010;151:12:5916-5926. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999484/ https://doi.org/10.1210/en.2010-0165
Kaneda H. The analysis of PGRMC1 expression and function in endometrial cancer cells. Juntendo Medical Journal. 2011;57:4:336-344. https://doi.org/10.14789/pjmj.57.336
Burns KA, Korach KS. Estrogen receptors and human disease: an update. Arch Toxicol. 2012;86:10:1491-1504. https://doi.org/10.1007/s00204-012-0868-5
Fujimoto J, Sakaguchi H, Aoki I, Khatun S, Toyoki H. Steroid receptors and metastatic potential in endometrial cancers. Steroid Biochemistry and Molecular Biology. 2000;75:4-5:209-212. https://doi.org/10.1016/s0960-0760(00)00176-x
Arnett-Mansfield RL, deFazio A, Wain GV, Jaworski RC, Byth K, Mote PA. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res. 2001;61:4576-4582.
Jazaeri AA, Nunes KJ, Dalton MS, Xu M, Shupnik MA. Welldifferentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene. 2001;20:47:6965-6969. https://doi.org/10.1038/sj.onc.1204809
Fujimoto J, Ichigo S, Hori M, Nishigaki M, Tamaya T. Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors. Tumour Biol. 1995;16:4:254-260.

Close metadata